Skandinaviska Enskilda Banken (SEB)
YMAB

Skandinaviska Enskilda Banken (SEB)’s Y-mAbs Therapeutics YMAB Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-37,900
Closed -$1.08M – 1080
2021
Q3 		$1.08M Buy
37,900
+36,900
+3,690% +$1.16M 0.01% 773
2021
Q2 		$34K Hold
1,000
– – ﹤0.01% 1014
2021
Q1 		$30K Hold
1,000
– – ﹤0.01% 1084
2020
Q4 		$50K Hold
1,000
– – ﹤0.01% 1086
2020
Q3 		$38K Buy
+1,000
New +$39.8K ﹤0.01% 981

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s YMAB Position: Q4 2021 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Y-mAbs Therapeutics (YMAB) in Q4 2021, closing a stake of 37,900 shares — an estimated $1.08M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in YMAB in Q3 2020 and held it in 5 quarters. The position peaked at $1.08M in Q3 2021. 97 funds tracked by Wall St. Rank hold YMAB as of Q4 2021.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Y-mAbs Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 37,900 Y-mAbs Therapeutics shares in Q4 2021, an estimated $1.08M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Y-mAbs Therapeutics in Q3 2020 and held it in 5 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Y-mAbs Therapeutics position peaked at $1.08M in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2021.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2021, filed 10 Feb 2022.